DXCM · Insider Trading

DexCom, Inc.

Every open-market purchase and sale reported by DXCM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
19
code S
Reporting Insiders
25
current holders
DXCM — Recent Form 4 Transactions (latest 2026-09-16)
FiledInsiderRole TypeSharesValue
2026-09-16 Michael Jon Brown EVP Chief Legal Compliance Off Sell — —
2026-09-16 NICHOLAS AUGUSTINOS Director Sell — —
2026-09-14 Jereme M Sylvain EVP, Chief Financal Officer Sell — —
2026-09-10 Glenn S Boehnlein Director A — —
2026-08-28 Sadie Stern EVP Chief People & Culture Off Sell — —
2026-08-25 Sadie Stern EVP Chief People & Culture Off F — —
2026-08-25 Jereme M Sylvain EVP, Chief Financal Officer F — —
2026-08-25 Jacob Steven Leach President, CEO, and Director F — —
2026-08-25 Michael Jon Brown EVP Chief Legal Compliance Off F — —
2026-08-24 KEVIN R SAYER Executive Chair Sell — —
2026-08-17 Michael Jon Brown EVP Chief Legal Compliance Off Sell — —
2026-08-13 NICHOLAS AUGUSTINOS Director G — —
2026-08-13 Bridgette P Heller Director Sell — —
2026-08-04 MARK G FOLETTA Director Sell — —
2026-07-21 KEVIN R SAYER Executive Chair Sell — —
2026-07-16 Michael Jon Brown EVP Chief Legal Compliance Off Sell — —
2026-07-07 KEVIN R SAYER Executive Chair Sell — —
2026-06-17 Michael Jon Brown EVP Chief Legal Compliance Off Sell — —
2026-06-17 MARK G FOLETTA Director Sell — —
2026-06-05 Jon Coleman EVP, Chief Commercial Officer Sell — —
2026-06-01 RENEE D GALA Director A — —
2026-06-01 Richard Alexander Collins Director A — —
2026-06-01 Euan A. Ashley Director A — —
2026-06-01 Rimma Driscoll Director A — —
2026-06-01 Albert Frederick Osterloh IV Director A — —
2026-06-01 Bridgette P Heller Director A — —
2026-06-01 MARK G FOLETTA Director A — —
2026-06-01 NICHOLAS AUGUSTINOS Director A — —
2026-06-01 Kyle Malady Director A — —
2026-06-01 STEVEN R ALTMAN Director A — —
2026-05-27 Jon Coleman EVP, Chief Commercial Officer F — —
2026-05-27 Sadie Stern EVP Chief People & Culture Off F — —
2026-05-27 Jereme M Sylvain EVP, Chief Financal Officer F — —
2026-05-27 Michael Jon Brown EVP Chief Legal Compliance Off F — —
2026-05-27 Jacob Steven Leach President, CEO, and Director F — —
2026-05-26 KEVIN R SAYER Executive Chair Sell — —
2026-05-19 Michael Jon Brown EVP, Chief Legal Officer Sell — —
2026-05-14 Bridgette P Heller Director Sell — —
2026-05-11 STEVEN R ALTMAN Director G — —
2026-05-11 MARK G FOLETTA Director G — —
2026-05-11 Richard Alexander Collins Director G — —
2026-05-11 NICHOLAS AUGUSTINOS Director G — —
2026-04-16 Michael Jon Brown EVP, Chief Legal Officer Sell — —
2026-03-18 Michael Jon Brown EVP, Chief Legal Officer Sell — —
2026-03-10 Jon Coleman EVP, Chief Commercial Officer A — —
2026-03-10 Jacob Steven Leach President, CEO, and Director MIXED — —
2026-03-10 Sadie Stern EVP, Chief HR Officer MIXED — —
2026-03-10 Michael Jon Brown EVP, Chief Legal Officer MIXED — —
2026-03-10 Jereme M Sylvain EVP, Chief Financal Officer MIXED — —
2026-03-10 KEVIN R SAYER Executive Chair MIXED — —
DXCM — Current Insider Holders
InsiderRole Shares HeldValue
— Director 2,241,911 —
— Executive Chairman 493,056 —
— President, CEO, and Director 466,204 —
— Director 380,545 —
— Director 359,833 —
— Executive Chair 302,214 —
— EVP Global Business Services I 208,023 —
— EVP, Chief Financal Officer 146,828 —
— EVP Chief People & Culture Off 126,043 —
— EVP Managing Director Dexcom V 124,775 —
— Director 123,210 —
— EVP, Chief Commercial Officer 100,361 —
— EVP Chief Legal Compliance Off 99,885 —
— EVP Regulatory Strategy Clinic 89,515 —
— General Manager, EMEA 84,034 —
— CTO 75,833 —
— Director 69,232 —
— EVP Chief Commercial Officer 66,641 —
— Director 63,348 —
— EVP Operations 58,469 —
— Director 57,183 —
— SVP, CFO 54,949 —
— EVP Operations 54,468 —
— Director 52,820 —
— EVP Global Revenue 48,949 —
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the DXCM quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.